News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Takara Bio Obtains Clinical Trial Approval Of Gene Therapy Treatment For Chronic Granulomatosis
January 17, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Tokyo, Jan 11, 2007 (JCN) - Bio affiliate ViroMed Co., Ltd., based in Korea, announced the Korea Food & Drug Administration approval of their clinical trial of VM106, gene therapy treatment drug, for chronic granulomatosis.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Asia
MORE ON THIS TOPIC
Collaboration
Roche Broadens Global Clinical Trial Footprint With $480M+ South Korea Pledge
March 5, 2026
·
1 min read
·
Tristan Manalac
Insights
From Grants to Family Offices: Building a Unified Financing Strategy in Biotech
March 5, 2026
·
1 min read
·
Jennifer Smith-Parker
Podcast
UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
March 4, 2026
·
1 min read
·
Heather McKenzie
Immunology and inflammation
Sanofi Bets Up to $1.53B in Hong Kong Immuno Pact, Adding to String of Deals
March 4, 2026
·
2 min read
·
Tristan Manalac
